← All trials
NCT00630747
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2004
- Primary completion
- Jan 1, 2008
- Completion date
- Jan 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 94
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- ShireLead sponsor
- Federal University of Mato Grosso do SulOverall official - principal investigator
- University of IowaOverall official - principal investigator
- University of NebraskaOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Hospital DucuingOverall official - principal investigator
- Spitalul Clinic de CopiiOverall official - principal investigator
- University of CambridgeOverall official - principal investigator
- Johannes Gutenburg UniversityOverall official - principal investigator
- University of Naples Frederico IIOverall official - principal investigator
- University of PadovaOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- Federal University of Rio de JaneiroOverall official - principal investigator
- Sao Paulo State UniversityOverall official - principal investigator
- University Hospital Center of Sao Joao (UHCSJ)Overall official - principal investigator
- University of MontrealOverall official - principal investigator
- Drottning Silvias BarnsjukhusOverall official - principal investigator
- Mid-Illinois Hematology and Oncology AssociatesOverall official - principal investigator
- Comprehensive Cancer Centers of NevadaOverall official - principal investigator
- Federal University of Rio Grande do SulOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of UtahOverall official - principal investigator
- Franciscan Skemp HealthcareOverall official - principal investigator
- State University of New York, SyracuseOverall official - principal investigator
- University of MilanOverall official - principal investigator
- University of MelbourneOverall official - principal investigator
- University of Sao PauloOverall official - principal investigator
- RWTH Aachen UniversityOverall official - principal investigator
- University of NottinghamOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- University of BathOverall official - principal investigator
- Complexo HupesOverall official - principal investigator
- University of DuesseldorfOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Justus Liebig University GiessenOverall official - principal investigator
- St. Louis UniversityOverall official - principal investigator
- Karolinska InstituteOverall official - principal investigator
- University of HamburgOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- University of GoettingenOverall official - principal investigator
- ASO SS Antonio e Biagio e C Arrigo Alessandria, ItalyOverall official - principal investigator
- CHU Edouard HerriotOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.